United States· US:0002-9401_85d3d68b-57f9-45e6-a1a7-fa19bc843f33
Kisunla
A donanemab product containing donanemab, registered in United States by Eli Lilly and Company. The same ATC class is registered in 11 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Donanemab is registered in 11 of 19 countries.
Countries holding a registration under ATC N06DX05 (donanemab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Donanemab · ATC N06DX05
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DONANEMAB
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- N06DX05
- ATC class
- Donanemab
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1100029401011 VIAL, SINGLE-DOSE in 1 CARTON (0002-9401-01) / 20 mL in 1 VIAL, SINGLE-DOSE
- ndc110002-9401-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Donanemab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKISUNLAEli Lilly Nederland B.V., Utrecht
- SwitzerlandKisunla 350 mg, Konzentrat zur Herstellung einer InfusionslösungEli Lilly (Suisse) SA
- FinlandKisunlaEli Lilly Nederland B.V.
- United KingdomKisunla 350mg/20ml concentrate for solution for infusion vialsEli Lilly and Company Ltd
- IrelandKisunla 350 mg concentrate for solution for infusionEli Lilly Nederland B.V.
- IcelandKisunlaEli Lilly Nederland B.V.*
- Japanドナネマブ（遺伝子組換え）日本イーライリリー
- NetherlandsKisunla 350 mg concentraat voor oplossing voor infusieEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kisunla
- Liechtenstein · Kisunla
- Norway · Kisunla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d8cf2ef3-e5e1-4ad1-ac0c-ebc628052e7d GET /v1/drugs/d8cf2ef3-e5e1-4ad1-ac0c-ebc628052e7d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "17.5",
"substance": "DONANEMAB",
"productndc": "0002-9401",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761248",
"marketing_category": "BLA"
}See everything about donanemab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.